About Codexis (NASDAQ:CDXS)
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Industry, Sector and Symbol:
- Sector: Industrial Products
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CDXS
- CUSIP: 19200510
- Web: www.codexis.com
Capitalization:- Market Cap: $369.68 million
- Outstanding Shares: 48,324,000
Average Prices:- 50 Day Moving Avg: $6.17
- 200 Day Moving Avg: $5.20
- 52 Week Range: $3.60 - $7.95
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -42.50
- P/E Growth: -1.16
Sales & Book Value:- Annual Revenue: $43.16 million
- Price / Sales: 8.57
- Book Value: $0.63 per share
- Price / Book: 12.14
Profitability:- EBITDA: ($15,160,000.00)
- Net Margins: -40.70%
- Return on Equity: -83.39%
- Return on Assets: -45.44%
Debt:- Current Ratio: 3.06%
- Quick Ratio: 2.99%
Misc:- Average Volume: 170,353 shs.
- Beta: -1.44
- Short Ratio: 14.32
Frequently Asked Questions for Codexis (NASDAQ:CDXS)
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.13) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.13). The firm earned $10.30 million during the quarter, compared to analyst estimates of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The business's revenue for the quarter was down 35.6% on a year-over-year basis. During the same period last year, the company earned $0.12 earnings per share. View Codexis' Earnings History.
When will Codexis make its next earnings announcement?
Where is Codexis' stock going? Where will Codexis' stock price be in 2017?
4 analysts have issued 1 year target prices for Codexis' shares. Their forecasts range from $5.50 to $11.00. On average, they anticipate Codexis' stock price to reach $7.81 in the next twelve months. View Analyst Ratings for Codexis.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include AC Immune SA (ACIU), Abeona Therapeutics (ABEO), ANI Pharmaceuticals (ANIP), WAVE Life Sciences (WVE), Mesoblast Limited (MESO), Celyad SA (CYAD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), ImmunoGen (IMGN), Kala Pharmaceuticals (KALA), Agenus (AGEN), Adamas Pharmaceuticals (ADMS), Cara Therapeutics (CARA), Arbutus Biopharma Corporation (ABUS), Celldex Therapeutics (CLDX) and Idera Pharmaceuticals (IDRA).
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Bernard J. Kelley, Chairman of the Board
- John J. Nicols, President, Chief Executive Officer, Director
- Gordon T. Sangster, Chief Financial Officer, Senior Vice President
- Douglas T. Sheehy J.D., Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
- Michael Douglas Arthur Aldridge, Senior Vice President - Corporate & Strategic Development
- James Lalonde, Senior Vice President, Research & Development
- Thomas R. Baruch J.D., Chairman Emeritus
- Pam P. Cheng, Director
- Kathleen Sereda Glaub, Director
- Patrick Y. Yang, Director
Who owns Codexis stock?
Codexis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
VIVO VENTURES VII, LLC
(6.30%). Company insiders that own Codexis stock include Bernard J Kelley, Dennis P Wolf, James Lalonde, Patrick Y Yang, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.
How do I buy Codexis stock?
Shares of Codexis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Codexis' stock price today?
One share of Codexis stock can currently be purchased for approximately $7.65.
MarketBeat Community Rating for Codexis (NASDAQ CDXS)MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Codexis (NASDAQ:CDXS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $7.81 (2.12% upside) |
Consensus Price Target History for Codexis (NASDAQ:CDXS)
Analysts' Ratings History for Codexis (NASDAQ:CDXS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/13/2017 | Jefferies Group LLC | Boost Price Target | Buy | $9.00 -> $11.00 | N/A |  |
| 10/13/2017 | HC Wainwright | Boost Price Target | Buy -> Buy | $8.00 -> $8.50 | N/A | |
| 1/26/2017 | First Analysis | Downgrade | Overweight -> Equal Weight | $5.50 | N/A | |
| 1/4/2017 | Ladenburg Thalmann Financial Services | Upgrade | Neutral -> Buy | $6.25 | N/A | |
(Data available from 10/16/2015 forward)
Earnings History for Codexis (NASDAQ:CDXS)Earnings History by Quarter for Codexis (NASDAQ CDXS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.17) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($0.13) | ($0.13) | $9.61 million | $10.30 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.15) | ($0.18) | $9.23 million | $7.97 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.11) | ($0.12) | $9.15 million | $10.00 million | View | Listen | |
| 11/8/2016 | Q3 | ($0.14) | $0.06 | $7.41 million | $14.90 million | View | Listen | |
| 8/9/2016 | Q216 | $0.03 | $0.12 | $15.10 million | $16.00 million | View | Listen | |
| 5/9/2016 | Q1 | ($0.15) | ($0.11) | $7.49 million | $8.00 million | View | Listen | |
| 3/3/2016 | Q4 | ($0.04) | $0.02 | $11.63 million | $11.60 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.11) | $0.13 | $8.85 million | $17.40 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.14) | ($0.14) | $7.34 million | $6.02 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.12) | ($0.14) | $8.00 million | $6.80 million | View | Listen | |
| 3/3/2015 | Q414 | $0.01 | $0.07 | $13.30 million | $14.20 million | View | Listen | |
| 11/4/2014 | Q314 | ($0.06) | ($0.05) | $9.00 million | $7.47 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.15) | ($0.22) | $8.50 million | $6.60 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.10) | ($0.17) | $10.00 million | $7.10 million | View | Listen | |
| 3/11/2014 | Q413 | ($0.21) | ($0.26) | $10.00 million | $9.50 million | View | Listen | |
| 11/12/2013 | Q313 | ($0.31) | ($0.24) | $8.50 million | $3.90 million | View | Listen | |
| 8/9/2013 | Q2 2013 | ($0.28) | ($0.33) | $9.00 million | $6.97 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.36) | ($0.25) | $7.63 million | $11.48 million | View | Listen | |
| 2/27/2013 | Q4 2012 | ($0.34) | ($0.41) | $9.33 million | $7.90 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.15) | ($0.06) | $25.88 million | $26.34 million | View | N/A | |
| 8/9/2012 | | ($0.18) | ($0.15) | | | View | N/A | |
| 5/10/2012 | | ($0.15) | ($0.21) | | | View | N/A | |
| 2/7/2012 | | ($0.11) | ($0.15) | | | View | N/A | |
| 11/1/2011 | | ($0.08) | ($0.08) | | | View | N/A | |
| 7/28/2011 | | ($0.10) | ($0.14) | | | View | N/A | |
| 5/5/2011 | | ($0.07) | ($0.10) | | | View | N/A | |
| 2/3/2011 | | ($0.06) | ($0.01) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Codexis (NASDAQ:CDXS)2017 EPS Consensus Estimate: ($0.35)
2018 EPS Consensus Estimate: ($0.13)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q2 2017 | 2 | ($0.14) | ($0.12) | ($0.13) |
| Q3 2017 | 2 | ($0.17) | ($0.14) | ($0.16) |
| Q4 2017 | 1 | $0.04 | $0.04 | $0.04 |
| Q1 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q2 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q3 2018 | 1 | ($0.07) | ($0.07) | ($0.07) |
| Q4 2018 | 1 | $0.20 | $0.20 | $0.20 |
(Data provided by Zacks Investment Research)
Dividend History for Codexis (NASDAQ:CDXS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Codexis (NASDAQ:CDXS)Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 63.62%
Insider Trades by Quarter for Codexis (NASDAQ:CDXS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/14/2017 | Ventures Vii Affiliates F Vivo | Major Shareholder | Sell | 1,060,000 | $5.78 | $6,126,800.00 | |
| 11/15/2016 | Patrick Y Yang | Director | Buy | 10,000 | $4.83 | $48,300.00 | |
| 9/8/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 111,600 | $4.25 | $474,300.00 | |
| 8/29/2016 | Dennis P Wolf | Director | Sell | 18,000 | $4.22 | $75,960.00 | |
| 8/24/2016 | Bernard J Kelley | Director | Sell | 12,643 | $4.26 | $53,859.18 | |
| 8/16/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 86,894 | $4.25 | $369,299.50 | |
| 8/15/2016 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 50,000 | $4.27 | $213,500.00 | |
| 8/4/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 80,000 | $4.22 | $337,600.00 | |
| 11/11/2015 | James Lalonde | SVP | Sell | 9,441 | $3.52 | $33,232.32 | |
| 9/11/2015 | Patrick Y Yang | Director | Buy | 10,000 | $3.47 | $34,700.00 | |
| 9/10/2015 | Bernard J. Kelley | Director | Sell | 5,200 | $3.45 | $17,940.00 | |
| 8/24/2015 | Patrick Y Yang | Director | Buy | 10,000 | $3.84 | $38,400.00 | |
| 8/14/2015 | Patrick Y Yang | Director | Buy | 20,000 | $3.97 | $79,400.00 | |
| 6/15/2015 | Dennis P Wolf | Director | Sell | 35,416 | $4.10 | $145,205.60 | |
| 11/18/2014 | Patrick Y Yang | Director | Buy | 20,000 | $2.35 | $47,000.00 | |
| 11/17/2014 | Patrick Y Yang | Director | Buy | 20,000 | $2.34 | $46,800.00 | |
| 8/12/2014 | Patrick Y Yang | Director | Buy | 60,000 | $2.22 | $133,200.00 | |
| 3/8/2013 | John J Nicols | CEO | Buy | 27,000 | $2.42 | $65,340.00 | |
| 3/7/2013 | John J Nicols | CEO | Buy | 54,000 | $2.22 | $119,880.00 | |
| 3/4/2013 | David D O'toole | CFO | Buy | 10,000 | $2.02 | $20,200.00 | |
| 11/12/2012 | David D O'toole | CFO | Buy | 5,000 | $2.20 | $11,000.00 | |
| 9/14/2012 | David D O'toole | CFO | Buy | 5,000 | $2.78 | $13,900.00 | |
| 9/14/2012 | Douglas T Sheehy | SVP | Sell | 3,800 | $2.76 | $10,488.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Codexis (NASDAQ:CDXS)
Latest Headlines for Codexis (NASDAQ:CDXS)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Issue Forecasts for Codexis, Inc.'s Q4 2017 Earnings (CDXS)
www.americanbankingnews.com - October 16 at 5:18 AM |
| Codexis, Inc. (CDXS) Price Target Raised to $11.00
www.americanbankingnews.com - October 13 at 7:02 PM |
 | Codexis Reaches Analyst Target Price
www.thestreet.com - October 13 at 5:41 PM |
| HC Wainwright Boosts Codexis, Inc. (CDXS) Price Target to $8.50
www.americanbankingnews.com - October 13 at 7:34 AM |
| Codexis And Nestle Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
www.thestreet.com - October 12 at 10:55 PM |
 | Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership
finance.yahoo.com - October 12 at 5:53 PM |
| ETFs with exposure to Codexis, Inc. : October 12, 2017
finance.yahoo.com - October 12 at 5:53 PM |
| Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017
finance.yahoo.com - October 11 at 6:34 PM |
| Codexis, Inc. (CDXS) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:56 PM |
| 3 Top Small-Cap Stocks to Buy in October
finance.yahoo.com - October 4 at 12:23 PM |
| Codexis, Inc. (CDXS) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 2 at 3:50 PM |
| Codexis, Inc. (CDXS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 1 at 2:50 AM |
| Codexis, Inc. (CDXS) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - September 27 at 6:20 AM |
| Codexis (CDXS) & Bio-Techne Corp (TECH) Head to Head Analysis
www.americanbankingnews.com - September 20 at 2:22 PM |
| Codexis, Inc. (CDXS) Major Shareholder Ventures Vii Affiliates F. Vivo Sells 1,060,000 Shares
www.americanbankingnews.com - September 18 at 10:26 PM |
| Comparing Codexis (CDXS) and Its Rivals
www.americanbankingnews.com - September 17 at 10:32 PM |
| $10.00 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - September 10 at 5:40 AM |
 | Codexis (CDXS) Presents At 24th Annual NewsMakers In The Biotech Industry - Slideshow
seekingalpha.com - September 9 at 9:44 PM |
| -$0.14 Earnings Per Share Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - September 8 at 2:20 PM |
| Codexis, Inc. (CDXS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 6 at 2:28 AM |
| Codexis to Present at Four Investment Conferences in September
finance.yahoo.com - August 31 at 4:58 PM |
 | 3 Stocks Set to Pop
www.fool.com - August 16 at 2:24 PM |
| Financial Comparison: Codexis (NASDAQ:CDXS) & Repros Therapeutics (RPRX)
www.americanbankingnews.com - August 14 at 8:06 PM |
| Q3 2017 EPS Estimates for Codexis, Inc. (NASDAQ:CDXS) Lowered by Jefferies Group
www.americanbankingnews.com - August 14 at 3:34 AM |
| HC Wainwright Analysts Give Codexis, Inc. (NASDAQ:CDXS) a $8.00 Price Target
www.americanbankingnews.com - August 13 at 3:32 PM |
| Codexis, Inc. (NASDAQ:CDXS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 12 at 2:32 AM |
| Jefferies Group Brokers Reduce Earnings Estimates for Codexis, Inc. (CDXS)
www.americanbankingnews.com - August 11 at 1:22 PM |
| Edited Transcript of CDXS earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:17 PM |
| Codexis, Inc. (CDXS) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - August 9 at 11:16 PM |
| Codexis reports 2Q loss
finance.yahoo.com - August 9 at 10:18 PM |
| Codexis Reports Financial Results for the Second Quarter of 2017
finance.yahoo.com - August 9 at 5:14 PM |
 | Codexis (CDXS) Says Court Ordered Summary Judgment of Patent Infringement against EnzymeWorks
www.streetinsider.com - August 9 at 2:53 AM |
| Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks
finance.yahoo.com - August 8 at 4:47 PM |
 | Codexis to Hold 2017 Second Quarter Conference Call on August 9
feeds.benzinga.com - August 2 at 8:21 AM |
| Codexis, Inc. (NASDAQ:CDXS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 18 at 1:45 PM |
| $10.04 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - July 13 at 11:04 AM |
| ETFs with exposure to Codexis, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 6:04 PM |
| Analysts Anticipate Codexis, Inc. (CDXS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 11 at 12:22 PM |
 | Codexis reports 1Q loss
marketbeat.com - May 9 at 7:04 PM |
| Delta Technology Holdings Is A Deep Value Play On The Fine Chemical Industry Rebound In China
seekingalpha.com - May 2 at 3:59 PM |
| Codexis (CDXS) Secures 2nd Multi-Year Agreement in Food Industry with Tate & Lyle
www.streetinsider.com - March 31 at 9:23 PM |
 | Codexis, Inc. :CDXS-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
us.rd.yahoo.com - March 15 at 4:35 PM |
| Q4 2016 Codexis Inc Earnings Release - After Market Close
biz.yahoo.com - March 9 at 4:48 PM |
| CODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 9 at 4:48 PM |
| Codexis Inc Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - March 9 at 4:48 PM |
| Codexis to Hold 2016 Fourth Quarter and Full Year Conference Call on March 9
feeds.benzinga.com - March 2 at 7:54 AM |
 | What's in Store for KBR Inc. (KBR) this Earnings Season?
www.nasdaq.com - February 21 at 2:25 PM |
| Deere (DE) Q1 Earnings: A Beat in Store for the Stock?
www.nasdaq.com - February 13 at 4:49 PM |
 | Codexis to Commercially Supply Proprietary Enzyme to Tate & Lyle
www.marketwatch.com - December 6 at 12:02 PM |
 | 7:03 am Codexis appoints Bernard J. Kelley as Chairman, effective November 29
us.rd.yahoo.com - December 2 at 4:34 PM |
Codexis (CDXS) Chart for Monday, October, 16, 2017
